Stoke Therapeutics, Inc.

Edward Kaye is stepping down as CEO of Stoke Therapeutics, just weeks after securing a vital deal with Biogen on its late-stage Dravet syndrome candidate, zorevunersen. The announcement of Kaye’s depa

In what observers are calling a sensible deal for both sides, Stoke Therapeutics and Biogen revealed on 18 February that they will collaborate on development and commercialization of Stoke’s antisense

US initial public offerings by biopharmaceutical companies appear to be on the rise in 2024 with nine during the first quarter, including Boundless Bio Inc. ’s $100m IPO on 27 March, outpacing 2023 w

After nearly 10 years developing its lead candidate for Dravet syndrome, Stoke Therapeutics ’ persistence looks to be finally paying off. New Phase I/IIa data shows STK-001 produced consistent reduct